Jason Kim, MD
Vascular Surgery · Raleigh, NCNPI 1376733873
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Bard Peripheral Vascular, Inc. accounts for 72.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $6,217 and has fallen 99.6% since, to $25 in 2025.
Across 40 payments — averaging $201.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$6K
- W. L. Gore & Associates, Inc.$1K
- Lemaitre Vascular, Inc.$375
- Covidien LP$160
- Medtronic$92
- Cvrx, Inc.$51
- plus $93 from 3 others
What the payments were for
- Consulting fees$2,97537%
- Travel & lodging$4,06351%
- Food & beverage$1,00613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 12 | $5,831 |
| W. L. Gore & Associates, Inc. | 16 | $1,442 |
| Lemaitre Vascular, Inc. | 1 | $375 |
| Covidien LP | 4 | $160 |
| Medtronic | 3 | $92 |
| Cvrx, Inc. | 1 | $51 |
| Terumo Medical Corporation | 1 | $50 |
| Novo Nordisk | 1 | $25 |
| Medistim USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CROSSER$1,054
- GORE TAG Thoracic Endoprosthesis$1,052
- VALVULOTOM$375
- ProGrip$118
How this compares
$8,044 in reported general payments places this provider in the 70th percentile of 119 vascular surgery providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $43,619 |
| XareltoRivaroxaban | 40 | $36,456 |
| ClopidogrelClopidogrel Bisulfate | 81 | $878 |
| Cilostazol | 34 | $506 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 61 | $384 |
| Warfarin Sodium | 24 | $303 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Raleigh
- Robert MendesRaleigh$408K
- Ellen DillavouRaleigh$284K
- Christopher McQuinnRaleigh$77K
- Joseph SalfityRaleigh$13K
- Kirk CharlesRaleigh$8K
- Liliana NanezRaleigh$7K
- Heather WaldropRaleigh$5K
- Jacek PaszkowiakRaleigh$4K
- James FogartieRaleigh$3K
- Frank ArkoCharlotte$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.